CHRU Hopital Sainte Marguerite

Sainte-Marguerite, France

CHRU Hopital Sainte Marguerite

Sainte-Marguerite, France
SEARCH FILTERS
Time filter
Source Type

Deville J.-L.,Institute Paoli Calmettes | Gravis G.,Institute Paoli Calmettes | Gravis G.,French Institute of Health and Medical Research | Salem N.,Oncology and Radiotherapy Institute | And 13 more authors.
European Journal of Cancer Care | Year: 2010

Removal of residual masses after chemotherapy in non-seminomatous germ cell tumours (NSGCTs) remains the standard of care. We evaluated in a retrospective and monocentric study potential prognostic factors. Fifty-one patients underwent surgery after chemotherapy for NSGCT. We estimated event-free survival with Kaplan-Meier method and used Cox proportional hazards regression analysis to assess the prognostic significance of risk factors. Histology of residual masses revealed fibrosis in 25 (49%), mature teratoma in 18 (35%) and viable germ cells in 8 (16%). Alpha-fetoprotein mean level at diagnosis was higher in patients with residual masses showing mature teratoma and/or viable malignant cells (P= 0.036). In multivariate analysis, poor prognosis group according to International Germ Cell Cancer Collaborative Group was associated with worse outcome compared with good and intermediate prognosis groups (hazard ratio for events = 26.4; 95% confidence interval 2.46-283.9; P= 0.006) and primary testicular NSGCT was associated with better event-free survival than extragonadal NSGCTs (hazard ratio for events = 0.04; 95% confidence interval 0.004-0.48; P= 0.01). Resection of residual masses after chemotherapy in NSGCT results in favourable long-term survival in most patients. Our results compared favourably with those reported from higher volume centres. © 2009 The Authors European Journal of Cancer Care © 2009 Blackwell Publishing Ltd.

Loading CHRU Hopital Sainte Marguerite collaborators
Loading CHRU Hopital Sainte Marguerite collaborators